These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26992951)

  • 1. Management after first-line antiresorptive treatment for postmenopausal osteoporosis.
    Paccou J
    Joint Bone Spine; 2016 Jul; 83(4):373-5. PubMed ID: 26992951
    [No Abstract]   [Full Text] [Related]  

  • 2. Is it time for treat to target strategy in osteoporosis?
    Chapurlat R
    Joint Bone Spine; 2016 Jul; 83(4):381-3. PubMed ID: 26875064
    [No Abstract]   [Full Text] [Related]  

  • 3. Bisphosphonates in osteoporosis: NICE and easy?
    Harvey NC; McCloskey E; Kanis JA; Compston J; Cooper C
    Lancet; 2017 Nov; 390(10109):2243-2244. PubMed ID: 29165263
    [No Abstract]   [Full Text] [Related]  

  • 4. Atypical fractures on long term bisphosphonates therapy.
    Hussein W; Cunningham C; Logan H; Fallon C; Murphy S
    Ir Med J; 2011; 104(10):308, 310. PubMed ID: 22256444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Osteoporosis and bisphosphonates].
    Zuber MA
    Z Rheumatol; 2007 Dec; 66(8):713-5. PubMed ID: 17955251
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide.
    Tan J; Sano H; Poole K
    BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31340943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial.
    Adami S; Libanati C; Boonen S; Cummings SR; Ho PR; Wang A; Siris E; Lane J; ; Adachi JD; Bhandari M; de Gregorio L; Gilchrist N; Lyritis G; Möller G; Palacios S; Pavelka K; Heinrich R; Roux C; Uebelhart D
    J Bone Joint Surg Am; 2012 Dec; 94(23):2113-9. PubMed ID: 23097066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.
    Gold DT; Martin BC; Frytak JR; Amonkar MM; Cosman F
    Curr Med Res Opin; 2007 Mar; 23(3):585-94. PubMed ID: 17355739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports.
    Lamy O; Fernández-Fernández E; Monjo-Henry I; Stoll D; Aubry-Rozier B; Benavent-Núñez D; Aguado P; Gonzalez-Rodriguez E
    Osteoporos Int; 2019 May; 30(5):1111-1115. PubMed ID: 30613866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
    Sánchez A; Blanco R
    Osteoporos Int; 2017 Mar; 28(3):1145-1147. PubMed ID: 27866217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment holidays in patients with postmenopausal osteoporosis: whom and when?
    Reyes García R; García Martín A; Muñoz-Torres M
    Endocrinol Nutr; 2012 Dec; 59(10):573-4. PubMed ID: 23031434
    [No Abstract]   [Full Text] [Related]  

  • 12. Current role for bone absorptiometry.
    Roux C; Briot K
    Joint Bone Spine; 2017 Jan; 84(1):35-37. PubMed ID: 27282091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab for the management of postmenopausal osteoporosis.
    Singer A; Grauer A
    Postgrad Med; 2010 Nov; 122(6):176-87. PubMed ID: 21084794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
    Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
    Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of long-term alendronate treatment on cortical thickness of the proximal femur.
    Unnanuntana A; Ashfaq K; Ton QV; Kleimeyer JP; Lane JM
    Clin Orthop Relat Res; 2012 Jan; 470(1):291-8. PubMed ID: 21773861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-minimization study comparing annual infusion of zoledronic acid or weekly oral alendronate in women with low bone mineral density.
    Chávez-Valencia V; Arce-Salinas CA; Espinosa-Ortega F
    J Clin Densitom; 2014; 17(4):484-9. PubMed ID: 24613450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of highly potent bisphosphonates in the treatment of osteoporosis.
    McClung M
    Curr Osteoporos Rep; 2003 Dec; 1(3):116-22. PubMed ID: 16036074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [FACT study].
    Tanaka I; Oshima H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():280-5. PubMed ID: 18161120
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treating with what? Therapy for how long?].
    MMW Fortschr Med; 2005 Dec; 147(51-52):62-3. PubMed ID: 16402713
    [No Abstract]   [Full Text] [Related]  

  • 20. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.